These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 23053137)

  • 1. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective flutemetamol positron emission tomography and histopathology in normal pressure hydrocephalus.
    Rinne JO; Frantzen J; Leinonen V; Lonnrot K; Laakso A; Virtanen KA; Solin O; Kotkansalo A; Koivisto A; Sajanti J; Karppinen A; Lehto H; Rummukainen J; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajarvi M; Grachev ID
    Neurodegener Dis; 2014; 13(4):237-45. PubMed ID: 24296542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic effectiveness of quantitative [¹⁸F]flutemetamol PET imaging for detection of fibrillar amyloid β using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus.
    Leinonen V; Rinne JO; Wong DF; Wolk DA; Trojanowski JQ; Sherwin PF; Smith A; Heurling K; Su M; Grachev ID
    Acta Neuropathol Commun; 2014 Apr; 2():46. PubMed ID: 24755237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.
    Leinonen V; Rinne JO; Virtanen KA; Eskola O; Rummukainen J; Huttunen J; von Und Zu Fraunberg M; Nerg O; Koivisto AM; Rinne J; Jääskeläinen JE; Buckley C; Smith A; Jones PA; Sherwin P; Farrar G; McLain R; Kailajärvi M; Heurling K; Grachev ID
    Eur J Neurol; 2013 Jul; 20(7):1043-52. PubMed ID: 23398333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.
    Wong DF; Moghekar AR; Rigamonti D; Brašić JR; Rousset O; Willis W; Buckley C; Smith A; Gok B; Sherwin P; Grachev ID
    Mol Imaging Biol; 2013 Apr; 15(2):230-7. PubMed ID: 22878921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.
    Wolk DA; Grachev ID; Buckley C; Kazi H; Grady MS; Trojanowski JQ; Hamilton RH; Sherwin P; McLain R; Arnold SE
    Arch Neurol; 2011 Nov; 68(11):1398-403. PubMed ID: 21747004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain uptake and safety of Flutemetamol F 18 injection in Japanese subjects with probable Alzheimer's disease, subjects with amnestic mild cognitive impairment and healthy volunteers.
    Miki T; Shimada H; Kim JS; Yamamoto Y; Sugino M; Kowa H; Heurling K; Zanette M; Sherwin PF; Senda M
    Ann Nucl Med; 2017 Apr; 31(3):260-272. PubMed ID: 28181118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a difference in regional read [
    Farrar G; Molinuevo JL; Zanette M
    Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1299-1308. PubMed ID: 30863934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of amyloid distribution by [
    Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
    Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parametric imaging and quantitative analysis of the PET amyloid ligand [(18)F]flutemetamol.
    Heurling K; Buckley C; Van Laere K; Vandenberghe R; Lubberink M
    Neuroimage; 2015 Nov; 121():184-92. PubMed ID: 26209803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
    de Lartigue J
    Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
    Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.